Collegium Pharmaceutical Valuation
| COLL Stock | USD 45.79 0.51 1.13% |
At this time, the firm appears to be undervalued. Collegium Pharmaceutical shows a prevailing Real Value of $49.99 per share. The current price of the firm is $45.79. Our model approximates the value of Collegium Pharmaceutical from analyzing the firm fundamentals such as Profit Margin of 0.08 %, current valuation of 1.96 B, and Return On Equity of 0.23 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Collegium Pharmaceutical's valuation include:
Undervalued
Today
Please note that Collegium Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Collegium Pharmaceutical is based on 3 months time horizon. Increasing Collegium Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Collegium stock is determined by what a typical buyer is willing to pay for full or partial control of Collegium Pharmaceutical. Since Collegium Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Collegium Stock. However, Collegium Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 45.79 | Real 49.99 | Target 53.67 | Hype 45.66 |
The intrinsic value of Collegium Pharmaceutical's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Collegium Pharmaceutical's stock price.
Estimating the potential upside or downside of Collegium Pharmaceutical helps investors to forecast how Collegium stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Collegium Pharmaceutical more accurately as focusing exclusively on Collegium Pharmaceutical's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Collegium Pharmaceutical's intrinsic value based on its ongoing forecasts of Collegium Pharmaceutical's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Collegium Pharmaceutical's closest peers.
Collegium Pharmaceutical Cash |
|
Collegium Revenue by Product
Collegium Pharmaceutical Total Value Analysis
Collegium Pharmaceutical is currently expected to have valuation of 1.96 B with market capitalization of 1.43 B, debt of 859.3 M, and cash on hands of 122.72 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Collegium Pharmaceutical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.96 B | 1.43 B | 859.3 M | 122.72 M |
Collegium Pharmaceutical Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Collegium Pharmaceutical is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in March.Collegium Pharmaceutical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Collegium Pharmaceutical has an asset utilization ratio of 37.96 percent. This suggests that the Company is making $0.38 for each dollar of assets. An increasing asset utilization means that Collegium Pharmaceutical is more efficient with each dollar of assets it utilizes for everyday operations.Collegium Pharmaceutical Profitability Analysis
Taking into consideration Collegium Pharmaceutical's profitability measurements, Collegium Pharmaceutical is performing exceptionally good at this time. It has a great probability to showcase excellent profitability results in March. Profitability indicators assess Collegium Pharmaceutical's ability to earn profits and add value for shareholders.Net Income | First Reported 2013-12-31 | Previous Quarter 12 M | Current Value 31.5 M | Quarterly Volatility 18.6 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.65 | 0.69 |
|
|
For Collegium Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Collegium Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Collegium Pharmaceutical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Collegium Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Collegium Pharmaceutical over time as well as its relative position and ranking within its peers.
Collegium Pharmaceutical Earnings per Share Projection vs Actual
The next projected EPS of Collegium Pharmaceutical is estimated to be 1.6198 with future projections ranging from a low of 1.469 to a high of 1.84. Collegium Pharmaceutical's most recent 12-month trailing earnings per share (EPS TTM) is at 1.63. Please be aware that the consensus of earnings estimates for Collegium Pharmaceutical is based on EPS before non-recurring items and includes expenses related to employee stock options.Collegium Pharmaceutical Earnings Estimation Breakdown
The calculation of Collegium Pharmaceutical's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Collegium Pharmaceutical is estimated to be 1.6198 with the future projection ranging from a low of 1.469 to a high of 1.84. Please be aware that this consensus of annual earnings estimates for Collegium Pharmaceutical is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.47 Lowest | Expected EPS | 1.84 Highest |
Collegium Pharmaceutical Earnings Projection Consensus
Suppose the current estimates of Collegium Pharmaceutical's value are higher than the current market price of the Collegium Pharmaceutical stock. In this case, investors may conclude that Collegium Pharmaceutical is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Collegium Pharmaceutical's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 6 | 65.24% | 0.0 | 1.6198 | 1.63 |
Collegium Pharmaceutical Ownership Allocation
The majority of Collegium Pharmaceutical outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Collegium Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Collegium Pharmaceutical. Please pay attention to any change in the institutional holdings of Collegium Pharmaceutical as this could imply that something significant has changed or is about to change at the company.Collegium Pharmaceutical Profitability Analysis
The company reported the previous year's revenue of 631.45 M. Net Income was 69.19 M with profit before overhead, payroll, taxes, and interest of 667.51 M.About Collegium Pharmaceutical Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Collegium Pharmaceutical. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Collegium Pharmaceutical based exclusively on its fundamental and basic technical indicators. By analyzing Collegium Pharmaceutical's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Collegium Pharmaceutical's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Collegium Pharmaceutical. We calculate exposure to Collegium Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Collegium Pharmaceutical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 433.9 M | 455.6 M | |
| Pretax Profit Margin | 0.14 | 0.15 | |
| Operating Profit Margin | 0.24 | 0.25 | |
| Net Profit Margin | 0.10 | 0.10 | |
| Gross Profit Margin | 0.69 | 0.65 |
Collegium Pharmaceutical Growth Indicators
Investing in growth stocks can be very risky. If the company such as Collegium Pharmaceutical does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 40.4 M | |
| Quarterly Earnings Growth Y O Y | 2.132 | |
| Forward Price Earnings | 6.0938 |
Collegium Pharmaceutical Current Valuation Indicators
Collegium Pharmaceutical's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Collegium Pharmaceutical's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Collegium Pharmaceutical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Collegium Pharmaceutical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Collegium Pharmaceutical's worth.When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. Projected growth potential of Collegium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Collegium Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.132 | Earnings Share 1.63 | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.